Literature DB >> 33809047

Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet.

Isabella Gigante1, Valeria Tutino1, Francesco Russo2, Valentina De Nunzio1, Sergio Coletta3, Raffaele Armentano3, Alberto Crovace4, Maria Gabriella Caruso5, Antonella Orlando2, Maria Notarnicola1.   

Abstract

The administration of a ketogenic diet (KD) has been considered therapeutic in subjects with irritable bowel syndrome (IBS). This study aimed to investigate the molecular mechanisms by which a low-carbohydrate diet, such as KD, can improve gastrointestinal symptoms and functions in an animal model of IBS by evaluating possible changes in intestinal tissue expression of endocannabinoid receptors. In rats fed a KD, we detected a significant restoration of cell damage to the intestinal crypt base, a histological feature of IBS condition, and upregulation of CB1 and CB2 receptors. The diet also affected glucose metabolism and intestinal membrane permeability, with an overexpression of the glucose transporter GLUT1 and tight junction proteins in treated rats. The present data suggest that CB receptors represent one of the molecular pathways through which the KD works and support possible cannabinoid-mediated protection at the intestinal level in the IBS rats after dietary treatment.

Entities:  

Keywords:  cannabinoid receptors; irritable bowel syndrome; ketogenic diet; rat model

Mesh:

Substances:

Year:  2021        PMID: 33809047      PMCID: PMC7999285          DOI: 10.3390/ijms22062880

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  52 in total

1.  Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation.

Authors:  Q Wang; X Wang; A Hernandez; S Kim; B M Evers
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

Review 2.  Stress and visceral pain: from animal models to clinical therapies.

Authors:  Muriel Larauche; Agata Mulak; Yvette Taché
Journal:  Exp Neurol       Date:  2011-05-06       Impact factor: 5.330

Review 3.  Endocannabinoids in the gastrointestinal tract.

Authors:  Yunna Lee; Jeongbin Jo; Hae Young Chung; Charalabos Pothoulakis; Eunok Im
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-18       Impact factor: 4.052

4.  Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group.

Authors:  Eric H Kossoff; Beth A Zupec-Kania; Per E Amark; Karen R Ballaban-Gil; A G Christina Bergqvist; Robyn Blackford; Jeffrey R Buchhalter; Roberto H Caraballo; J Helen Cross; Maria G Dahlin; Elizabeth J Donner; Joerg Klepper; Rana S Jehle; Heung Dong Kim; Y M Christiana Liu; Judy Nation; Douglas R Nordli; Heidi H Pfeifer; Jong M Rho; Carl E Stafstrom; Elizabeth A Thiele; Zahava Turner; Elaine C Wirrell; James W Wheless; Pierangelo Veggiotti; Eileen P G Vining
Journal:  Epilepsia       Date:  2008-09-23       Impact factor: 5.864

5.  Diets that differ in their FODMAP content alter the colonic luminal microenvironment.

Authors:  Emma P Halmos; Claus T Christophersen; Anthony R Bird; Susan J Shepherd; Peter R Gibson; Jane G Muir
Journal:  Gut       Date:  2014-07-12       Impact factor: 23.059

6.  Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.

Authors:  Adam Fabisiak; Marcin Włodarczyk; Natalia Fabisiak; Martin Storr; Jakub Fichna
Journal:  J Gastrointestin Liver Dis       Date:  2019-12-09       Impact factor: 2.008

7.  The ketogenic diet as a treatment paradigm for diverse neurological disorders.

Authors:  Carl E Stafstrom; Jong M Rho
Journal:  Front Pharmacol       Date:  2012-04-09       Impact factor: 5.810

8.  Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis.

Authors:  Mengmeng Lv; Xingya Zhu; Hao Wang; Feng Wang; Wenxian Guan
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

9.  Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice.

Authors:  David Ma; Amy C Wang; Ishita Parikh; Stefan J Green; Jared D Hoffman; George Chlipala; M Paul Murphy; Brent S Sokola; Björn Bauer; Anika M S Hartz; Ai-Ling Lin
Journal:  Sci Rep       Date:  2018-04-27       Impact factor: 4.379

Review 10.  Endocannabinoids in neuroendopsychology: multiphasic control of mitochondrial function.

Authors:  Alistair Nunn; Geoffrey Guy; Jimmy D Bell
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

View more
  4 in total

Review 1.  Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome.

Authors:  Stuart M Brierley; Beverley Greenwood-Van Meerveld; Giovanni Sarnelli; Keith A Sharkey; Martin Storr; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-09-27       Impact factor: 73.082

Review 2.  The Microbiome and Gut Endocannabinoid System in the Regulation of Stress Responses and Metabolism.

Authors:  Raj Kamal Srivastava; Beat Lutz; Inigo Ruiz de Azua
Journal:  Front Cell Neurosci       Date:  2022-05-11       Impact factor: 6.147

3.  The Ketogenic Diet Improves Gut-Brain Axis in a Rat Model of Irritable Bowel Syndrome: Impact on 5-HT and BDNF Systems.

Authors:  Antonella Orlando; Guglielmina Chimienti; Maria Notarnicola; Francesco Russo
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

4.  The Ketogenic Diet Reduces the Harmful Effects of Stress on Gut Mitochondrial Biogenesis in a Rat Model of Irritable Bowel Syndrome.

Authors:  Guglielmina Chimienti; Antonella Orlando; Angela Maria Serena Lezza; Benedetta D'Attoma; Maria Notarnicola; Isabella Gigante; Vito Pesce; Francesco Russo
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.